174 related articles for article (PubMed ID: 2935249)
1. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
Egorin MJ; Van Echo DA; Whitacre MY; Forrest A; Sigman LM; Engisch KL; Aisner J
Cancer Res; 1986 Mar; 46(3):1513-20. PubMed ID: 2935249
[TBL] [Abstract][Full Text] [Related]
2. Metabolism and disposition of menogaril (NSC 269148) in the rabbit.
Dodion P; Egorin MJ; Engisch KL; Bachur NR
Cancer Res; 1985 Nov; 45(11 Pt 1):5352-7. PubMed ID: 2932217
[TBL] [Abstract][Full Text] [Related]
3. Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction.
Egorin MJ; Conley BA; Forrest A; Zuhowski EG; Sinibaldi V; Van Echo DA
Cancer Res; 1987 Nov; 47(22):6104-10. PubMed ID: 2959359
[TBL] [Abstract][Full Text] [Related]
4. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
Ratain MJ; Schilsky RL
Cancer Res; 1986 Sep; 46(9):4874. PubMed ID: 2942243
[No Abstract] [Full Text] [Related]
5. The disposition of the new anthracycline antibiotic, menogarol, in mice.
Dodion P; Chang BK; Egorin MJ; Olman EA; Engisch KL; Bachur NR
Drug Metab Dispos; 1984; 12(3):365-70. PubMed ID: 6145565
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey.
Adams WJ; McGovren JP; Dalm EA; Brewer JE; Hosley JD
Cancer Res; 1989 Nov; 49(22):6328-36. PubMed ID: 2529962
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical investigation of 7-con-O-methylnogaril, a new anthracycline antibiotic.
Dorr FA; Von Hoff DD; Kuhn JG; Schwartz R; Kisner DL
Cancer Res; 1986 May; 46(5):2562-5. PubMed ID: 2938729
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of menogaril administered as a 72-hour continuous i.v. infusion.
Long HJ; Powis G; Schutt AJ; Moertel CG
Cancer Treat Rep; 1987 Jun; 71(6):593-8. PubMed ID: 2953414
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of 7-con-O-methylnogarol in patients with solid tumors.
Zanette ML; Tirelli U; Sorio R; Zadro D; Figoli F; Monfardini S; D'Incalci M
Cancer Chemother Pharmacol; 1987; 20(1):67-70. PubMed ID: 2957106
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of menogaril administered as an intermittent daily infusion for 5 days.
Sigman LM; Van Echo DA; Egorin MJ; Whitacre MY; Aisner J
Cancer Treat Rep; 1986 Jun; 70(6):721-5. PubMed ID: 2942244
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of menogaril in patients with advanced cancer.
Brown TD; Donehower RC; Grochow LB; Rice AP; Ettinger DS
J Clin Oncol; 1987 Jan; 5(1):92-9. PubMed ID: 2949065
[TBL] [Abstract][Full Text] [Related]
12. Plasma pharmacokinetics and urinary excretion of hexamethylene bisacetamide metabolites.
Egorin MJ; Zuhowski EG; Cohen AS; Geelhaar LA; Callery PS; Van Echo DA
Cancer Res; 1987 Nov; 47(22):6142-6. PubMed ID: 3664514
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1.
Foster BJ; Wiegand RA; LoRusso PM; Baker LH
Clin Cancer Res; 1995 Aug; 1(8):831-7. PubMed ID: 9816052
[TBL] [Abstract][Full Text] [Related]
14. Effects of 7-R-O-methylnogarol (menogaril) on L1210 cell progression in vitro and in vivo.
Adams EG; Bhuyan BK
Cancer Res; 1986 Dec; 46(12 Pt 1):6125-30. PubMed ID: 2946401
[TBL] [Abstract][Full Text] [Related]
15. Activity of the anthracycline agent, 7-con-O-methylnogarol (7-OMEN), administered orally to mice bearing P388 or L1210 leukemia.
McGovren JP
Cancer Treat Rep; 1980; 64(4-5):727-9. PubMed ID: 6448690
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of intravenous menogaril administered intermittently.
Dodion P; Sessa C; Joss R; Crespeigne N; Willems Y; Kitt M; Abrams J; Finet C; Brewer JE; Adams WJ
J Clin Oncol; 1986 May; 4(5):767-74. PubMed ID: 2939203
[TBL] [Abstract][Full Text] [Related]
17. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics of oxaliplatin: a critical review.
Graham MA; Lockwood GF; Greenslade D; Brienza S; Bayssas M; Gamelin E
Clin Cancer Res; 2000 Apr; 6(4):1205-18. PubMed ID: 10778943
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical and pharmacokinetic trial of oral menogaril administered on three consecutive days.
Dodion P; de Valeriola D; Crespeigne N; Peeters B; Wery F; van Berchem C; Piccart M; Tueni E; Joggi J; Kenis Y
Eur J Cancer Clin Oncol; 1988 Jun; 24(6):1019-26. PubMed ID: 2970391
[TBL] [Abstract][Full Text] [Related]
20. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
Tan CT; Hancock C; Steinherz P; Bacha DM; Steinherz L; Luks E; Winick N; Meyers P; Mondora A; Dantis E
Cancer Res; 1987 Jun; 47(11):2990-5. PubMed ID: 3471321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
